Driven to extend the lives of cancer patients
Celcuity was founded in 2012 by Brian Sullivan and Lance Laing, PhD to develop a better way to treat the cellular abnormalities that drive tumor growth. Our team of drug development scientists, biochemists, and molecular biologists are advancing new targeted therapies for cancer.
Unlocking the potential of treating cancers that involve the PAM pathway
Gedatolisib is a potential first-in-class pan-PI3K, mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (PAM) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer, is ongoing. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing.